Hoy, 25 years later we continue passionately committed to patients developing precision therapies for diseases with important non -covered medical needs. In these 25 years, we have also been a quarry of great professionals, who began or took and flourished with us and then departed to lead their own companies or occupy positions of responsibility in large pharmas. We are proud to have contributed to enrich the Spanish biotechnological system.
In these years we went from being fascinated by the function of certain genes in certain diseases, such as LSD1 and others, to draw molecules on a blank paper, and refine them until they try them in humans. Today, We have two molecules, in phase III and in phase II, in the field of certain neuropsychiatric disorders and certain specific types of cancer. And other molecules come behind.
The excellence of our science has many objective evidence. The most recent our selection thanks to the project Vandam To participate in the Important European Interest Project (IPCEI) Med4curewhere we have received through CDTI a subsidy of 13.3 million euros. Vandam seeks to investigate the effect of our epigenetic molecules in certain orphan diseases and align our innovation with the recent view of the EU to boost strategic sufficiency in research and health resilience.
Med4Cure will mobilize up to one billion euros in public financing from 6 EU countries to support 14 projects that involve 24 companies, including Oryzon.
This subsidy will increase our financial solidity, already reinforced after the recent investment led by US investors of 30 million euros announced last April in a capital expansion that was extended from the initial 25 million and ended up being remarkably envelope.
This financial strengthening of almost 50 million dollars It has had broad echo in the international community given the situation of volatility and uncertainty of the markets that has punished the entire Biotech International sector.
This success is the reflection of the excellence of our molecules and credibility generated by their data. Thus we have been able to attract prestigious psychiatrists of the US academic world to help us refine our Phase III Protocol with Vafidemstat in Personality Limit Disorder (TLP) already interact with the FDA.
We have also seen how the flower and cream of the American lung oncology began a PHASE I/II TEST With our drug iadademstat In small cell lung cancer on the front line. This essay, which pays the NCI of the US.involves 22 hospitals including the Memorial Sloan Kettering, Dana Farber, MD Anderson, Yale and Johns Hopkins hospitals and others. Also prestigious North American hospitals are conducting sophisticated studies in acute myeloid leukemiawhich are the continuation of Oryzon with good results (ALICE), and are also exploring the potential in myelodysplastic syndrome.
With the resources received, the company will continue the Clinical development of our most advanced molecules, Vafidemstat and Iadademstat, as well as CMC activities and other regulatory initiatives, and will enhance our legal and audit preparation for a possible double price in Nasdaq.
The company has important challenges in the coming months, Get the approval of the FDA of the Phase III Protocol in TLP and explore additional financing chances that allow us to cover it completely, including possible alliances with pharmas.
We will display doubt In other orphan indications focusing on the treatment of aggression. And we will explore iadademstat In several orphan diseases and we will see how NCI trials show results that can change the vision of our drug in cancer.
The European bet for the Biotechnology and medicine as the Med4cure project is crucial for companies like Oryzon to develop innovative treatments. This support allows European companies to lead the scientific avant -garde, addressing global medical challenges.